DXNVX Holds 'Future of Korean Bio' Meeting with Leading Bio Scholars

DXVX announced on the 26th that it held a roundtable meeting titled "The Future of Korean Bio" by inviting leading domestic and international scholars in the fields of bio and vaccines.

The roundtable, held on the 23rd at the Lotte Hotel in Sogong-dong, was attended by DXVX President Kwon Kyu-chan, Evicsgen CEO Han Sung-jun, Kori Company CEO Kim Jang-hee, and Kori USA CEO Park Sang-tae. External participants included Dr. David Weiner from the Wistar Institute, USA, Dr. Joseph Kim, CEO of AGENTA (a cancer treatment developer in the USA), Dr. Song Manki, Deputy Director General of the International Vaccine Institute, and Dr. Choi Jong-soon, Deputy Director of the Korea Basic Science Institute (KBSI), who exchanged diverse opinions on the Korean bio and vaccine industries.

Dr. Weiner is recognized as the pioneer of DNA vaccines and currently serves as Vice President of the Wistar Institute under the U.S. National Cancer Institute (NCI), Chair of the WW Smith Cancer Research Fund, and a board member of the International Society for Vaccines. He recently visited Korea to discuss global business cooperation plans related to new drug development with DXVX.

At the roundtable, scientific and academic discussions were held on diagnosing the Korean bio industry and preparations that companies and academia should make to prepare for the endemic era. First, Dr. Weiner and Dr. Joseph Kim shared their views on the characteristics of the recent pandemic, advances in bio technology, and the global growth potential of the Korean bio industry.

Dr. Weiner stated, "The characteristics of this pandemic included the rapid development and supply of COVID vaccines, the emergence and spread of various variants, and it was a period when the importance of the bio industry was highlighted more than ever."

He added, "The emergence of new technologies such as AI through machine learning will bring significant changes to the future development of the bio industry," and "The Korean bio industry will continue to grow due to its talented human resources, active government support, and high interest from companies."

Dr. Joseph Kim also evaluated that Korea possesses favorable conditions for bio industry growth, including world-class human resources and large-scale commercial production infrastructure.

Discussions also continued on the difficulties faced by domestic companies in the research and development process and ways to overcome them to grow into global bio companies.

Dr. Joseph Kim suggested, "Unlike U.S. companies, Korean bio companies tend to focus on short-term results and risk-averse management, which act as obstacles to becoming global companies. It is necessary to have a long-term perspective and make bold R&D investments like global companies."

Dr. Song Manki emphasized the need for global cooperation in vaccine development, stating, "Although the government has recently made significant investments in vaccine research and production infrastructure in places like Andong and Hwasun, there are still limited companies in Korea capable of conducting clinical trials from Phase 1 to Phase 3, and the environment remains challenging."

Dr. Choi Jong-soon highlighted the importance of bio technology development after the pandemic and the government's strong support will, suggesting, "It is time to actively utilize government support to discover promising domestic platform technologies and make bold investments in commercialization."

President Kwon Kyu-chan, who hosted the event, said, "I am grateful to have had a meaningful time exploring the path forward for the domestic bio industry in the endemic era," and added, "We will actively pursue strategic alliances with global companies for research on new drug candidates currently under internal development at DXVX."

Following this roundtable, DXVX plans to regularly meet with domestic and international experts, including Professor Weiner, to discuss various cooperation plans such as global collaboration in new drug development and talent exchange.

Meanwhile, DXVX is expanding its business into various healthcare fields such as pharmaceutical distribution and new drug development, and has recently been actively engaged in developing proprietary new drug substances and attracting top talent.

This content was produced with the assistance of AI translation services.